---
schema_version: "secwatch.filing_event.v1"
accession: "0001617669-23-000039"
form_type: "8-K"
ticker: null
cik: "0001617669"
company_name: "Unique Fabricating, Inc."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:25:56.064592+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# UFAB gets NYSE American extension to March 31, 2024 to file late reports; sale process continues

## Summary
- NYSE American granted extension through March 31, 2024 to cure delinquent 10-K (FY2022) and 10-Qs (Q1, Q2 2023).
- Company pursuing strategic alternatives, including sale of business, with milestone completion deadline of October 31, 2023.
- No assurances given that UFAB will regain compliance or maintain NYSE listing.

## SEC filing metadata
- accession: 0001617669-23-000039
- form_type: 8-K
- cik: 0001617669
- company_name: Unique Fabricating, Inc.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1617669/000161766923000039/0001617669-23-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1617669/000161766923000039/ufab-20231003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001617669-23-000039
- JSON: https://secwatch.observer/filing/0001617669-23-000039.json
- Plain text: https://secwatch.observer/filing/0001617669-23-000039.txt

## Key facts
- Listing & Compliance Notices
  Unique Fabricating, Inc. received a nyse_american extension granted notice regarding late filing (rules 134, 1101, 1007).
  - Exchange: nyse american
  - Notice: extension granted
  - Deficiency: late filing
  - Rules: 134, 1101, 1007
  source text: October 3, 2023, the NYSE American granted an extension through March 31, 2024 for the Company to cure its filing deficiency. Pursuant to Section 1007 of the Company Guide, an issuer is required to submit an extension request when it is unable to cure the filing deficiency within the initial six-month period of the maximum 12-month cure period from when it became delinquent. A company’s common stock will continue to be listed and traded on the NYSE during the cure periods, subject to a company’s compliance with other continued listing requirements. The current noncompliance with the NYSE listi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1617669/000161766923000039/0001617669-23-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.